Investment Thesis
Iterum Therapeutics faces severe financial distress with negative stockholders' equity of -$7.4M, indicating liabilities exceed assets. The company is generating minimal revenue ($390K) while burning significant cash ($15.3M operating cash flow negative) and accumulating losses ($20.4M net loss), with no clear path to profitability in the near term.
Strengths
- Adequate short-term liquidity with current ratio of 2.13x and $11.0M cash on hand providing near-term runway
- Substantial reduction in diluted EPS loss (57.4% improvement YoY) suggests some operational progress or accounting improvements
- Pharmaceutical sector positioning could enable future value creation if pipeline advances succeed
Risks
- Critical: Negative stockholders' equity of -$7.4M indicates technical insolvency and structural balance sheet deterioration
- Severe cash burn of $15.3M annually with only $11.0M cash reserves provides approximately 9 months of runway at current burn rate
- Revenue of only $390K is inconsistent with meaningful commercial operations, suggesting pre-commercial or failed commercialization stage
- Substantial long-term debt of $20.0M against negative equity creates debt service risk without profitability
- Zero insider buying activity in last 90 days signals lack of management confidence in company trajectory
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue growth trajectory and achievement of commercial milestones
- Progress toward positive EBITDA or sustained operating cash flow improvement
- Changes in stockholders' equity and path to balance sheet solvency
- Debt refinancing needs and ability to secure additional capital
Financial Metrics
Revenue
390.0K
Net Income
-20.4M
EPS (Diluted)
$-0.51
Free Cash Flow
-15.3M
Total Assets
32.5M
Cash
11.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-4,351.3%
Net Margin
-5,225.4%
ROE
N/A
ROA
-62.7%
FCF Margin
-3,915.9%
Balance Sheet & Liquidity
Current Ratio
2.13x
Quick Ratio
1.96x
Debt/Equity
N/A
Debt/Assets
122.7%
Interest Coverage
N/A
Long-term Debt
20.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-29T15:18:16.078460 |
Data as of: 2025-09-30 |
Powered by Claude AI